Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing in India

Background Despite expanding access to antiretroviral therapy (ART), most of the estimated 2.3 to 2.5 million HIV-infected individuals in India remain undiagnosed. The questions of whom to test for HIV and at what frequency remain unclear. Methods We used a simulation model of HIV testing and treatment to examine alternative HIV screening strategies: 1) current practice, 2) one-time, 3) every five years, and 4) annually; and we applied these strategies to three population scenarios: 1) the general Indian population (“national population”), i.e. base case (HIV prevalence 0.29%; incidence 0.032/100 person-years [PY]); 2) high-prevalence districts (HIV prevalence 0.8%; incidence 0.088/100 PY), and 3) high-risk groups (HIV prevalence 5.0%; incidence 0.552/100 PY). Cohort characteristics reflected Indians reporting for HIV testing, with a median age of 35 years, 66% men, and a mean CD4 count of 305 cells/µl. The cost of a rapid HIV test was $3.33. Outcomes included life expectancy, HIV-related direct medical costs, incremental cost-effectiveness ratios (ICERs), and secondary transmission benefits. The threshold for “cost-effective” was defined as 3x the annual per capita GDP of India ($3,900/year of life saved [YLS]), or for “very cost-effective” was <1x the annual per capita GDP ($1,300/YLS). Results Compared to current practice, one-time screening was very cost-effective in the national population (ICER: $1,100/YLS), high-prevalence districts (ICER: $800/YLS), and high-risk groups (ICER: $800/YLS). Screening every five years in the national population (ICER: $1,900/YLS) and annual screening in high-prevalence districts (ICER: $1,900/YLS) and high-risk groups (ICER: $1,800/YLS) were also cost-effective. Results were most sensitive to costs of care and linkage-to-care. Conclusions In India, voluntary HIV screening of the national population every five years offers substantial clinical benefit and is cost-effective. Annual screening is cost-effective among high-risk groups and in high-prevalence districts nationally. Routine HIV screening in India should be implemented.

[1]  E. Triche,et al.  Sexual risk behaviors among HIV-infected South Indian couples in the HAART era: implications for reproductive health and HIV care delivery , 2011, AIDS care.

[2]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[3]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[4]  R. Brookmeyer,et al.  Sensitivity and specificity of rapid HIV testing of pregnant women in India. , 2003, International journal of STD & AIDS.

[5]  D. Bachani,et al.  Are persons living with HIV timely accessing ART services in India? , 2009, Journal of the Indian Medical Association.

[6]  R. Feachem Commission on Macroeconomics and Health. , 2002, Bulletin of the World Health Organization.

[7]  P. Ghys,et al.  Improved estimates of India's HIV burden in 2006. , 2009, The Indian journal of medical research.

[8]  Milton C Weinstein,et al.  When to start antiretroviral therapy in resource-limited settings. , 2009, Annals of internal medicine.

[9]  I. Parker Facts and figures. , 1973, The Probe.

[10]  Matthias Egger,et al.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.

[11]  S. Solomon,et al.  Why are People Getting Tested? Self-Reported Reasons for Seeking Voluntary Counseling and Testing at a Clinic in Chennai, India , 2006, AIDS and Behavior.

[12]  A. Vibhagool,et al.  The TREAT Asia HIV Observational Database: Baseline and Retrospective Data , 2005, Journal of acquired immune deficiency syndromes.

[13]  R. Walensky,et al.  Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Sachs Macroeconomics and health: investing in health for economic development , 2002 .

[15]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[16]  M. Weinstein,et al.  Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. , 2008, The Journal of infectious diseases.

[17]  M. Weinstein,et al.  TREATMENT FOR PRIMARY HIV INFECTION: PROJECTING OUTCOMES OF IMMEDIATE, INTERRUPTED, OR DELAYED THERAPY , 2002, Journal of acquired immune deficiency syndromes.

[18]  K. Mayer,et al.  Expansion of HIV Laboratory Diagnostic Services in Chennai, India 2001–2006: Is the Growth Commensurate with the Need? , 2008, PloS one.

[19]  [Ministry of Health and Family Welfare; epidemiological survey, November 16 - 29, 1952]. , 1953, Revue medicale de Liege.

[20]  L. Dandona,et al.  Assessment of population-level effect of Avahan, an HIV-prevention initiative in India , 2011, The Lancet.

[21]  S. Anand,et al.  Usefulness of an observational database to assess antiretroviral treatment trends in India. , 2006, The National medical journal of India.

[22]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[23]  Milton C Weinstein,et al.  Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. , 2006, The New England journal of medicine.

[24]  M. Weinstein,et al.  Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d’Ivoire: a trial-based analysis , 2005, AIDS.

[25]  K. Mayer,et al.  Challenges of expansion of voluntary counselling and testing in India. , 2008, Sexual health.

[26]  D. Bachani,et al.  Two-year treatment outcomes of patients enrolled in India's national first-line antiretroviral therapy programme. , 2010, The National medical journal of India.

[27]  R. Steinbrook,et al.  HIV in India--a complex epidemic. , 2007, The New England journal of medicine.

[28]  R. Walensky,et al.  The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa , 2011, Journal of acquired immune deficiency syndromes.

[29]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[30]  K. Mayer,et al.  Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries. , 2005, The Indian journal of medical research.

[31]  G. Schmid,et al.  HIV Voluntary Counseling and Testing and Behavioral Risk Reduction in Developing Countries: A Meta-analysis, 1990–2005 , 2008, AIDS and Behavior.

[32]  M. Weinstein,et al.  Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy , 2007, AIDS.

[33]  Milton C Weinstein,et al.  Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.

[34]  R. Walensky,et al.  Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  T. Flanigan,et al.  Reasons for Modification of Generic Highly Active Antiretroviral Therapeutic Regimens Among Patients in Southern India , 2006, Journal of acquired immune deficiency syndromes.

[36]  T. Flanigan,et al.  Natural history of human immunodeficiency virus disease in southern India. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Walensky,et al.  Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness , 2010, PloS one.

[38]  P. Balakrishnan,et al.  Performance characteristics of a new rapid immunochromatographic test for the detection of antibodies to human immunodeficiency virus (HIV) types 1 and 2 , 2008, Journal of clinical laboratory analysis.

[39]  H. Gayle,et al.  Containing HIV/AIDS in India: the unfinished agenda. , 2006, The Lancet. Infectious diseases.

[40]  S. Solomon,et al.  AIDS in India , 2006, Postgraduate Medical Journal.

[41]  L. Dandona,et al.  Behavioral Surveillance of Premarital Sex Among Never Married Young Adults in a High HIV Prevalence District in India , 2010, AIDS and Behavior.

[42]  Douglas K Owens,et al.  Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. , 2005, The New England journal of medicine.

[43]  Connie Celum,et al.  Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis , 2010, The Lancet.

[44]  L. Dandona,et al.  Changing cost of HIV interventions in the context of scaling-up in India , 2008, AIDS.

[45]  M. Gold Cost-effectiveness in health and medicine , 2016 .

[46]  R. Walensky,et al.  Cost-Effectiveness of HIV Testing Referral Strategies among Tuberculosis Patients in India , 2010, PloS one.